1. Home
  2. NBY vs APRE Comparison

NBY vs APRE Comparison

Compare NBY & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

N/A

Current Price

$1.19

Market Cap

398.2M

Sector

N/A

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.84

Market Cap

6.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NBY
APRE
Founded
2000
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.2M
6.3M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
NBY
APRE
Price
$1.19
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.50
AVG Volume (30 Days)
1.1M
252.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
35.42
37.97
EPS
0.76
N/A
Revenue
$370,000.00
N/A
Revenue This Year
$23.91
N/A
Revenue Next Year
$32.05
N/A
P/E Ratio
$1.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.55
52 Week High
$19.95
$2.76

Technical Indicators

Market Signals
Indicator
NBY
APRE
Relative Strength Index (RSI) 41.33 55.05
Support Level $0.99 $0.55
Resistance Level $1.36 $1.02
Average True Range (ATR) 0.26 0.10
MACD 0.21 0.02
Stochastic Oscillator 31.95 74.15

Price Performance

Historical Comparison
NBY
APRE

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Share on Social Networks: